Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. - Wikidata - wikimedia - TriplyDB

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

http://www.wikidata.org/entity/Q34283690

about

Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy Do bisphosphonates cause femoral insufficiency fractures?Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project Association between alendronate and atypical femur fractures: a meta-analysis.Osteoporosis and ageing affects the migration of stem cells and this is ameliorated by transfection with CXCR4.A case of bilateral stress fractures in an old woman: three years of pain.The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.Bisphosphonate-associated peri-implant fractures: a new clinical entity? A series of 10 patients with 11 fractures.Atypical femur fractures: a review of the evidence and its implication to clinical practice Bisphosphonate-associated femur fractures have high complication rates with operative fixation.Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report Stress fractures in elderly patients.Caveats of bisphosphonate abuse.Bisphosphonate-induced atypical subtrochanteric femoral fracture.We need a break: Bisphosphonates Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.Burden of bisphosphonate-associated femoral fractures.The effect of parathyroid hormone and teriparatide on fracture healing.Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing: a cautionary tale from 2 cases Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.Progression of bisphosphonate-associated impending atypical femoral fracture despite prophylactic cephalomedullary nailing: A case report and review of literature.Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.Incidence of atypical nontraumatic diaphyseal fractures of the femur.Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use.

P2860

Q24198280-E268F258-755C-4A43-95A3-81272F662370 Q27021396-E0D9E475-CE10-4FF6-96DC-DEB01DF47110 Q27026618-0A5C6F9E-BBB7-47C1-B101-6493A158787A Q33596535-A2B096F7-A01E-4986-8614-6B9C7542124A Q33856984-5A34679C-A5CF-4659-9ED1-38B2B27DEF97 Q34230361-DB15D4CD-FCA2-4FDF-B6F6-75911FC7D804 Q35012189-8F685274-852D-41C9-BD34-ABF8B0A17FD9 Q36044297-073845E4-2632-4B53-8B46-971EA9A8E153 Q36059445-BD21EA27-8861-4ABA-B460-253F60164FE2 Q36083736-C7471621-49A6-4955-8D4B-64F09E512CFF Q36152236-2DE2CB28-5D77-4FB9-B961-51830EEA98F3 Q36427837-CF984175-A7D1-45C2-9735-70228A81F84D Q37135332-DCA11B34-11BF-445C-A583-E37F4AF40204 Q37357615-5FBD9DB7-6F6A-4E8E-B6E2-8AE4949F656A Q37432269-D5B221CF-8736-4E4E-95E7-41CC56C6377D Q37435405-8639EA84-9134-41A0-BBA0-6E139FA6F651 Q37945476-F890919D-A3BB-4B7F-801C-A6AC2DB4CE74 Q38065319-11BE3494-B513-4719-B4DE-B5BA00D8C3E6 Q38264342-3BA97B7D-5D51-414D-A62D-AA569828FFDC Q38391112-0CA8755E-F6A4-4A13-A351-05D9C8E921C5 Q38766431-2FC7D0BA-0FB7-49BB-A87F-30768204897D Q39054900-A4DDFE4A-27D9-4957-BB27-D65277DA2824 Q39625860-BF90D835-7404-4CC1-AB81-CC9B7BB96564 Q44364497-447C7307-E399-4E41-B788-4723B08D70EE Q50904368-DDFCC89D-7FAF-4875-8C76-5FF7785B462B Q55400006-15AB2B33-3A91-4E41-B877-3C1908F3A780

P2860

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

http://www.wikidata.org/entity/Q34283690

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@ast

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@en

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@nl

type

label

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@ast

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@en

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@nl

prefLabel

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@ast

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@en

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@nl

P1433

Q34283690-35E25547-C13A-4F16-B04C-159BE60366EC

P1476

Q34283690-DECF398E-5209-4A8D-A08B-3D56DF935674

P2093

Q34283690-63BAC53E-B220-4BFB-81CD-9010AD496995

Q34283690-8CDD06E9-488C-4CE9-8762-A8736D3391E1

Q34283690-B33ED093-E7FC-4E2E-A775-8FF31C1E1949

Q34283690-D309A936-F4AC-417B-BBCC-DAFCA8811297

P2860

Q34283690-01CA798A-8493-4841-80C5-3174B3D7E8E2

Q34283690-03D98467-2882-4380-A7AC-81C9C00C1182

Q34283690-04AEDB45-6E22-4380-872D-207C6055A2CD

Q34283690-065EC75D-44BA-4CEB-BDD6-44C8BC326E7F

Q34283690-08EA5278-56C3-4A8D-A1CF-EB80D78587DE

Q34283690-0AAD8BB1-777E-47A6-96C1-381141993706

Q34283690-0FBDC911-EB76-408C-BDE6-659594C93649

Q34283690-18386337-98B8-4242-AE21-4A968AD57DDE

Q34283690-195E5C12-7A3A-4EB8-9AC1-DB1F1995D091

Q34283690-1C6BFA14-2EC1-4A67-9DD2-01E37D9AD7F5

P2888

Q34283690-15819F89-34F3-4490-B654-EF58FB257C20

P304

Q34283690-17C3F170-C3A9-430A-B421-A052AF2DFFAA

P31

Q34283690-D13ED2A2-437F-43FB-B317-1D59A1489E3A

P356

Q34283690-E0CD52AD-00CB-4D02-971D-193EE13C9740

P407

Q34283690-47E4578C-E401-49D7-BC99-7E4C35D3EFD7

P433

Q34283690-F230BC4A-8166-44A7-AABD-3601FC577433

P478

Q34283690-A0FACDAE-7C89-4CF7-9E7B-7DD4A2BCB3A6

P577

Q34283690-B7597EB3-AEC5-486E-9BD2-FE88BA469382

P5875

Q34283690-45DA5DC3-F742-4953-B79A-C84743FD07C7

P6179

Q34283690-6B150B28-DEFB-4CCC-9EDC-A250D2467A1A

P698

Q34283690-5087A6D5-ACDB-4A3C-86C6-834149189C10

P932

Q34283690-2968DA93-3940-472A-A8E5-169EE2BC66A9

P356

S11999-010-1535-X

P1433

Clinical Orthopaedics and Related Research

P1476

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

@en

P2093

Ian A Harris

http://www.w3.org/2001/XMLSchema#string

Joseph D Isaacs

http://www.w3.org/2001/XMLSchema#string

Louis Shidiak

http://www.w3.org/2001/XMLSchema#string

Zoltan L Szomor

http://www.w3.org/2001/XMLSchema#string

P2860

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Severely suppressed bone turnover: a potential complication of alendronate therapy.

Influence of remodeling on the mineralization of bone tissue.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

P2888

s11999-010-1535-x

P304

3384-3392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11999-010-1535-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

468

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46108905

http://www.w3.org/2001/XMLSchema#string

P6179

1019788188

http://www.w3.org/2001/XMLSchema#string

P698

20809164

http://www.w3.org/2001/XMLSchema#string

P932

2974861

http://www.w3.org/2001/XMLSchema#string